Lansoprazole in the treatment of gastro-oesophageal reflux disease

Lansoprazole is more effective than H2 antagonists in the treatment and maintenance of remission of gastro-oesophageal reflux disease.

A systematic review including 8 studies with a total of 2840 subjects was abstracted in DARE.

The pooled odds ratio for healing was 6.3 (95% CI 4.2 to 9.4) for lansoprazole versus H2 antagonists (ranitidine or famotidine). No significant difference was observed between lansoprazole and omeprazole. There was no difference between 30 and 60 mg/day of lansoprazole (OR 1.4, 95% CI 0.6 to 3.2). The pooled OR for relapse within 1 year was 0.09 for lansoprazole 15 mg vs placebo, and 0.07 (95% CI 0.04 to 0.13) for lansoprazole 30 mg vs placebo. Both 15 and 30 mg of lansoprazole were more effective than ranitidine 600 mg/day in the maintenance of remission, with evidence of relapse in 31.4%, 20% and 67.5%, respectively.

Comment: The definion of healing varied in the different studies.

Ədəbiyyat

1. Manzionna G, Page F, Bianchi Porro G. Efficacy of lansoprazole in the short- and long-term treatment of gastro-oesophageal reflux disease: a systematic overview. Clin Drug Invest 1997;14:450-456.